Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Liabilities: 2018-2025

Historic Total Liabilities for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $6.2 million.

  • China SXT Pharmaceuticals' Total Liabilities fell 61.66% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.9 million, marking a year-over-year decrease of 6.63%. This contributed to the annual value of $6.2 million for FY2025, which is 32.33% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Total Liabilities stood at $6.2 million for FY2025, which was down 32.33% from $9.2 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Total Liabilities ranged from a high of $18.6 million in FY2021 and a low of $6.2 million during FY2025.
  • Over the past 3 years, China SXT Pharmaceuticals' median Total Liabilities value was $9.2 million (recorded in 2024), while the average stood at $10.1 million.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Total Liabilities spiked by 51.10% in 2021 and then tumbled by 38.12% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Liabilities (Yearly) stood at $18.6 million in 2021, then fell by 7.88% to $17.1 million in 2022, then fell by 13.19% to $14.9 million in 2023, then tumbled by 38.12% to $9.2 million in 2024, then slumped by 32.33% to $6.2 million in 2025.